drugset
drugset / Trial / NCT07583589

Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT07583589 ↗

Phase 2 Not yet recruiting 60 enrolled First Affiliated Hospital of Wenzhou Medical University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Nintedanib combined with or without Dextromethorphan for the treatment of IPF, with FVC as the primary efficacy endpoint to evaluate its effectivenes.

Timeline

Start
2026-05-12
Primary completion
2027-03-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dextromethorphan Unknown 30 mg Oral
Background Nintedanib Small molecule 100 mg —
Background Nintedanib Small molecule 150 mg —

Indications

idiopathic pulmonary fibrosis